Navigation Links
Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance
Date:12/10/2009

NEW YORK, Dec. 10 /PRNewswire-FirstCall/ --

  • Company remains focused on speeding innovation to patients and delivering greater value to customers.
  • Five strategic business units prepared to maximize growth opportunities in multiple therapeutic areas and geographies.
  • Lilly advances ranking to ninth in worldwide pharmaceutical sales; fastest growing top 10 pharma company in the U.S., major Europe and globally.
  • R&D pipeline boasts more than 60 molecules in clinical development, including 25 in Phases II and III.
  • Company expects 10 Phase III molecules in 2011, plans to launch 2 new medicines per year beginning in 2013.
  • Continued strong cash flow expected to fund R&D investment and business development transactions, while at least maintaining the current dividend.
  • 2010 EPS guidance set at $4.65 to $4.85, excluding the potential impact of health care reform in the U.S.
  • Longer-term guidance reconfirmed at low double-digit compound annual EPS growth between 2007 and 2011

At its annual meeting today with the investment community, Eli Lilly and Company (NYSE: LLY) highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.

"In 2009, Lilly has once again exhibited strong performance in a tough environment, and we've continued with a series of actions aimed at speeding innovation to patients and delivering greater value to our customers," said John C. Lechle
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... -- Neuralstem, Inc. (NYSE MKT: CUR) today reported that ... presented updated Phase I data from its spinal cord-derived ... of amyotrophic lateral sclerosis (ALS or Lou ... medical symposium in Bucharest, Romania , ... in Stem Cell Therapy," Dr. Feldman outlined the design ...
(Date:5/20/2013)... CHICAGO, Ill. , May 20, 2013 /PRNewswire/ ... the initiation of a Phase 3 clinical study ... to assess the effects of the investigational compound ... progression of kidney disease in patients with stage ... type 2 diabetes.  SONAR is a large, multinational, ...
(Date:5/20/2013)... , May 20, 2013 With herbal medicines ... available from the U.S. Pharmacopeial Convention (USP) will provide ... of the herbal ingredients used in these products. Today, ... in the new Herbal Medicines Compendium ( ... at hmc.usp.org . HMC ...
Breaking Medicine Technology:Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6New Compendium Offers Freely Available Testing Standards to Help Ensure the Quality of Herbal Ingredients Used in Traditional Medicines 2New Compendium Offers Freely Available Testing Standards to Help Ensure the Quality of Herbal Ingredients Used in Traditional Medicines 3
(Date:5/20/2013)... The automated external defibrillator market ... categories - semi-automated and fully automated defibrillators. Based ... categories, namely, hospitals, pre-hospital, public access, alternate care, ... Automated external defibrillators play an important role in ... Considering the life-saving potential of AEDs, legislations requiring ...
(Date:5/20/2013)... new healthcare bill proposes to have major ramifications in ... all the conditions were to be implemented or have ... 2014 to show anything. , According to Health ... forward to implement the health care law and establishing ... and West Virginia. HHS will continue to provide the ...
(Date:5/20/2013)... 20, 2013 Eben Pagan's ... the public creating a frenzy among business owners ... elite business training. WealthSpringMarketing.com's Tiffany Hendricks has published ... an exclusive bonus. , "Eben Pagan is a ... training to individuals serious about success," reports Hendricks. ...
(Date:5/20/2013)... According to a May 6, 2013 CBS ... Salons,” tanning salons in the US may soon ... Administration wants to see cancer warnings on indoor tanning ... of eighteen for the use of indoor tanning and sun ... has become increasingly common over the last few decades (Go ...
(Date:5/20/2013)... Lake City, UT (PRWEB) May 20, 2013 ... named one of Select Health’s Select 25 winners ... receive $2500 from Select Health. Know Greater Heroes is a ... local elementary schools to teach children how to eat right, ... student athletes participate in the Know Greater Heroes program each ...
Breaking Medicine News(10 mins):Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 2Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 3Health News:Review of Health Bill Impact in 2014 2Health News:Review of Health Bill Impact in 2014 3Health News:Eben Pagan's Accelerate: Review and Bonus Released By WealthSpringMarketing.com 2Health News:Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs 2Health News:SLCC Know Greater Heroes Program Named to Select 25 2Health News:SLCC Know Greater Heroes Program Named to Select 25 3
... Hologic, Inc. (Nasdaq: HOLX ) today announced that Glenn ... Global Healthcare Unplugged Conference in New York City on Tuesday, September ... Interested parties are invited to listen to a live audio ... company,s website at www.hologic.com/investor . An archive of ...
... , , , ... (Nasdaq: ZIXI ), the leader in email encryption services, today ... is a two-year extension of Humana,s original agreement which has now spanned ... ZixCorp licenses bringing the total to 36,000. , , ...
... in the September 2009 issue of the Journal of ... life prior to treatment can help predict the overall survival ... For those with advanced stage NSCLC, the median overall ... of patients surviving past the one year mark. To better ...
... study, approximately 20% of U.S. soldiers returning from Iraq ... substantial number with post-traumatic stress disorder (PTSD), and the ... unacceptable to Army commanders and the soldiers, families. ... doctors will now be able to forecast a soldier,s ...
... discounts, special promotions lead to greater alcohol consumption, study shows ... college bars lead to more intoxicated students and more health ... news that college students drink and the results can be ... the impact of drink discounts at college bars and found ...
... , , , WASHINGTON, Sept. ... flu, or H1N1 outbreak, in a recent article . , ... of the Mexican government in the fields of public awareness, rapid ... , The article noted "Mexico,s most effective action ...
Cached Medicine News:Health News:Zix Corporation and Humana Renew and Expand Exclusive Agreement 2Health News:Keeping the suicidal soldier alive 2Health News:College Students Get More Drunk When Drinks Are Cheap 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: